文献速递心力衰竭与心肌病

晚期癌症接受专业姑息治疗患者的心衰治疗:EMPATICC 试验

Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial).
PubMed 文献 · Eur Heart J · 2026-01-01

EMPATICC 试验在 5 个中心随机 93 例 4 期实体瘤、预期寿命 1–6 个月且接受专业姑息治疗的患者,1:1 双盲接受优化心衰治疗(最多四种药物)或安慰剂。30 天主要分层终点无组间差异(win ratio 0.95,95%CI 0.57–1.58;

要点

  • 晚期癌症姑息治疗患者中,优化心衰治疗未改善 30 天自我照护能力主要终点。
  • 30 天总死亡率 32%,组间无差异,提示该人群早期死亡风险高。
  • 30 天存活者中心衰治疗降低 NT-proBNP、提高 LVEF 并改善主观 wellbeing。

核心结论

  • 在晚期癌症接受专业姑息治疗且早期死亡率高的人群中,优化心衰治疗未改善患者自我照护能力。
  • 30 天存活者中生活质量指标和心脏生物标志物改善,提示个体化心衰治疗可能获益,属假设生成需验证。

研究设计与样本

  • 多中心(5 个中心)随机、双盲、安慰剂对照试验,1:1 分配至优化心衰治疗或安慰剂。
  • 纳入 93 例 4 期实体瘤、预期寿命 1–6 个月且接受专业姑息治疗的患者,需满足至少两项心血管风险标准和至少一项功能受限标准。
  • 优化心衰治疗最多四种药物:沙库巴曲缬沙坦、恩格列净、伊伐布雷定、羧基麦芽糖铁。
  • 主要分层终点为 30 天安慰剂对照期内:存活且能自行洗漱的天数、能行走 4 米的能力、患者整体评估(PGA)主观幸福感。

主要发现

  • 30 天总死亡率为 32%,组间无差异。

临床怎么用

  • 对晚期癌症接受专业姑息治疗且早期死亡风险高的患者,不应常规以改善自我照护能力为目的启动优化心衰治疗。
  • 对 30 天存活者,可考虑个体化心衰治疗以改善心脏生物标志物、LVEF 和主观幸福感,但需进一步验证。

局限性

  • 样本量小(93 例),主要终点可能把握度不足。
  • 30 天死亡率高(32%),存活者分析样本进一步减少且属亚组分析。
  • 随访仅 30 天,长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Advanced cancer may resemble a heart failure (HF)-like phenotype marked by cardiac wasting, dyspnoea, congestion, and/or physical dysfunction. The trial evaluated safety and efficacy of HF therapy among patients with advanced cancer receiving specialized palliative care to improve patients' self-care ability. METHODS: Patients with stage 4 solid tumours with a life expectancy of 1-6 months receiving specialized palliative care were enrolled. Patients were required to meet at least two cardiovascular risk criteria and at least one criterion for functional limitation. Participants were randomized 1:1 to receive optimized HF therapy (up to four drugs: sacubitril/valsartan, empagliflozin, ivabradine, ferric carboxymaltose) or placebo in a double-blind setting. The primary hierarchical endpoint included: (i) days alive and able to wash oneself, (ii) ability to walk 4 m, and (iii) self-reported patient global assessment (PGA) of subjective well-being, during the 30-day placebo-controlled phase. RESULTS: In five centres, 93 patients were randomized. The primary endpoint did not differ between groups (win ratio 0.95, 95% confidence interval [CI] 0.57-1.58; P = .83). Overall, mortality was 32% at 30 days (not different between groups). In patients alive at 30 days, HF therapy reduced N-terminal pro-B-type natriuretic peptide levels by 41% (P = .040), increased left ventricular ejection fraction by 2.9% (P = .036), and improved PGA scores (odds ratio 0.22, 95% CI 0.06-0.75; P = .016). CONCLUSIONS: In a population with advanced cancer receiving specialized palliative care and high early mortality, optimized HF therapy did not improve patients' self-care ability. Among survivors at 30 days, improvements in quality of life measures and cardiac biomarkers suggest potential benefit of individualized HF therapy, which is hypothesis generating and needs validation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Anker MS, Mahabadi AA, Totzeck M, et al. Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). Eur Heart J. 2026. PMID: 40884070. doi:10.1093/eurheartj/ehaf705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。